

IGNYTA, INC.

Uneventful 1Q14 Financials; Important RXDX Data at ASCO. Reiterate BUY

RXDX (NASDAQ)

Company & Market Data

Closing Price (as of May 9, 2014):	\$7.32
Rating:	BUY
Price Target:	\$20.00
52 Week Range:	\$1.00 - \$20.00
Shares Outstanding (MM):	20
Market Capitalization (MM):	\$143
Cash (MM):	\$100.4
Debt (MM):	\$9.0
Fiscal Year End:	Dec

Estimates

EPS	2013A	2014E	2015E
1Q	—	\$(0.28)A	\$(0.31)
Prior		\$(0.37)	\$(0.33)
2Q	—	\$(0.24)	\$(0.33)
Prior			\$(0.34)
3Q	—	\$(0.27)	\$(0.34)
Prior		\$(0.28)	\$(0.35)
4Q	—	\$(0.27)	\$(0.34)
Prior		\$(0.29)	\$(0.36)
Full Year	\$(1.94)	\$(1.06)	\$(1.33)
Prior	\$(3.83)	\$(1.15)	\$(1.38)
Revenue (MM)	\$0.0	\$0.0	\$0.0

Ignyta is developing personalized oncology drugs using diagnostic tests to identify patients most likely to respond to therapy. The company's lead product RXDX-101, is a TrkA/B/C, ROS1, ALK inhibitor in Phase I development for the treatment of solid tumors. Ignyta hopes to move the program into Phase II development in 2015 for multiple indications including NSCLC. The San Diego-based company is also in pre-clinical development of other targeted cancer therapies based on proprietary Oncolome molecular expression database.

On 5/12/14, RXDX reported uneventful 1Q14 financial results and provided incremental disclosure on the study design for STARTRK-1, a U.S. Phase I/II scheduled to begin enrollment in early 3Q14. We continue to view the upcoming oral presentation at the ASCO meeting Saturday 5/31/14 at 1:39 in Hall D2 as an important near term catalyst for RXDX shares. The presentation will discuss data from ALKA-372-001, an Italian Phase I study of RXDX-101 in treatment of solid tumors. Given differences in dose schedule (12 days of a 28-day cycle in ALKA-372-001 vs daily dosing in STARTRK-1), we encourage investors to focus primarily on the safety profile of RXDX-101 in the upcoming ASCO presentation. Currently, the ASCO conference program for oral presentations does not appear to include data from Trk-based targeted therapies in development at other companies. We believe the decision by the ASCO scientific committee to provide a high profile venue for RXDX-101 is a validation of RXDX's first mover advantage and believe the visibility may help accelerate enrollment in STARTRK-1. Importantly, the ASCO abstract that will be released May 14 was submitted in late January 2014 and, in our view, is unlikely to disclose any new data. However, the oral presentation will contain data through at least mid May and, in our view, may include results from substantially all patients enrolled in the Italian ALKA-372-001 Phase I study. Reiterate Buy rating and \$20.00 PT.

- **What's New?** RXDX presented uneventful 1Q14 financial results. On the financial results conference call, management provided incremental disclosure for the diagnostic testing protocols of the upcoming STARTRK-1 Phase I/II study. Diagnostic screening will be based on testing performed at each clinical site's testing lab and will incorporate a range of technologies for identifying translocations, point mutations and other gene variants. Given the limited availability of third party TrkB and TrkC assays, we expect STARTRK-1 to be enriched for TrkA patients. RXDX is developing proprietary assays to potentially be used in future studies. While we believe a standardized assay will be required for registration study, in our view, incorporating testing for a range of gene variants including both translocations and point mutations in early development should help the company identify an optimal diagnostic screening strategy for late-stage clinical trials.
- **Oral Presentation at ASCO Offers Near Term Catalyst:** Phase I RXDX-101 data will be presented at ASCO Saturday 5/31/14 at 1:39PM. The abstract (#2502) is entitled "Phase 1 open label, dose escalation study of RXDX-101, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations". The protocol called for patients to be dosed once daily for 4 days of a weekly cycle and for 3 weeks of a 4 week schedule for a total of 12 days of a 28 day cycle. RXDX expects to present data from about 20 patients at ASCO from all six dose cohorts enrolled in the study including the highest dose of 1600mg/kg. Data presented previously was from the 4 lowest dose cohorts.
- **Our Take:** We encourage investors to focus primarily on the adverse event profile at ASCO as RXDX moves into the STARTRK-1 study in early 3Q14 and would view any PRs or CRs as unexpected upside. We expect the continuous dosing Phase I study to provide the first meaningful glimpse into potential efficacy in late 4Q14 or 1Q15.
- **Detailed Review of 1Q14 Financial Results on Page 2.**

Disclosures and Analyst Certifications can be found in Appendix A.

570 Lexington Avenue 11th Floor • New York, New York 10022 • Telephone: 212-409-2000 • 800-LAD-THAL

Member: NYSE, NYSE MKT, FINRA, all other principal exchanges and SIPC

1Q14 Review

G&A: Administrative spending increased 367% to \$1.8M and was in line with our estimate of \$2.0M. The increase in administrative spending was primarily a result of increases in personnel costs as well as costs relating to the legal, investor relations, intellectual property and audit functions resulting from operating as a public company.

R&D: Research expenses totaled \$2.2M, compared \$0.4M for 1Q13, an increase of 243.2% but \$0.8M below our estimate. The increase related to the development of RXDX-101 and the company's Spark discovery programs.

EPS: RXDX reported EPS of (\$0.28), \$0.11 ahead of our (\$0.37) estimate drive by lower-than-expect R&D.

Table 1.

Ignyta 1Q14 EPS Review				
	1Q13A	1Q14A	Change	1Q14 - LTS Est.
Product Revenues	\$0.0	\$0.0		\$0.0
Other Revenues	0.0	0.0		0.0
Total Revenue	\$0.0	\$0.0		\$0.0
COGS	0.0	0.0		0.0
Gross profit	0.0	0.0		0.0
G&A	0.4	1.8	366.7%	2.0
Research & development	0.6	2.2	243.3%	3.0
Operating profit (loss)	(1.0)	(3.9)		(5.0)
Net Interest Income (expense)	(0.0)	(0.2)		(0.1)
Taxes	0.0	0.0		0.0
Net profit (loss)	(1.0)	(4.1)		(5.1)
Earnings (loss) per share from continuing ops	(\$1.55)	(\$0.28)		(\$0.37)
One-time Gains (expenses)	0.0	\$0.0		0.0
Net profit (loss) as reported	(1.0)	(4.1)		(5.1)
Earnings (loss) per share as reported	(\$1.55)	(\$0.28)		(\$0.37)
Weighted average common shares	0.7	14.5		13.9

Source: Company reports and Ladenburg Thalmann estimates

Table 2.

Ignyta Income Statement											
(In \$ millions)	2013A	1Q14A	2Q14E	3Q14E	4Q14E	2014E	1Q15E	2Q15E	3Q15E	4Q15E	2015E
Total product revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Revenue	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
COGS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
G&A	3.7	1.8	1.5	1.5	1.4	6.1	1.6	1.8	1.7	1.7	6.8
Research & development	3.2	2.2	3.3	4.0	4.0	13.5	4.7	4.9	5.2	5.2	20.0
Operating profit (loss)	(\$6.9)	(3.9)	(4.8)	(5.5)	(5.4)	(\$19.6)	(6.3)	(6.7)	(6.9)	(6.9)	(\$26.8)
Interest income	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.2
Interest expense	(0.2)	(0.1)	(0.2)	(0.2)	(0.2)	(0.7)	(0.2)	(0.2)	(0.2)	(0.2)	(0.7)
Other	(0.1)	(0.0)	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit (loss)	(7.2)	(4.1)	(4.9)	(5.6)	(5.5)	(20.1)	(6.4)	(6.8)	(7.1)	(7.0)	(27.3)
Earnings (loss) per share from continuing ops	(\$1.94)	(\$0.28)	(\$0.24)	(\$0.27)	(\$0.27)	(\$1.06)	(\$0.31)	(\$0.33)	(\$0.34)	(\$0.34)	(\$1.33)
One-time gains (expenses)	(\$0.54)	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Net income (loss) as reported	(14.2)	(4.1)	(4.9)	(5.6)	(5.5)	(20.1)	(6.4)	(6.8)	(7.1)	(7.0)	(27.3)
Earnings (loss) per share as reported	(\$3.83)	(\$0.28)	(\$0.24)	(\$0.27)	(\$0.27)	(\$1.06)	(\$0.31)	(\$0.33)	(\$0.34)	(\$0.34)	(\$1.33)
Weighted average common shares	3.7	14.5	20.5	20.5	20.5	19.0	20.5	20.5	20.5	20.5	20.5

Source: Company reports and Ladenburg Thalmann estimates

Company and Industry-Specific Risks

We think the primary risks of an investment in RXDX shares include, but are not limited to:

Clinical: While efficacy and safety of other ALK inhibitors for NSCLC has been well characterized in both clinical trials and commercial experience, there can be no assurance RXDX-101 will demonstrate clinically meaningful activity in NSCLC and other solid tumors. Additionally, RXDX-101 also inhibits ROS1 and TrkA/B/C. While there is a theoretical connection between inhibition of these tyrosine kinases and anti-tumor activity for a range of solid tumors including NSCLC, colon and glioblastoma, among others, there can be no assurances that future studies can be designed to evaluate the potential efficacy of co-inhibition of these tyrosine kinases or will confirm a positive impact on disease progression or survival, if a study is conducted. In the absence of clinical outcomes data, there can be no assurance that clinicians will accept or recognize the benefit of RXDX-101 over existing ALK inhibitors such as crizotinib. Additionally, the company is developing additional targeted cancer therapies based on its proprietary Oncolome database. There can be no assurance any future studies of pipeline programs will be adequate to support regulatory approval, reimbursement or commercial acceptance of pipeline programs. Lastly, RXDX relies on a virtual clinical development business model based on a small in-house management group and third party contractors. Loss of one or more executives could have an adverse impact of future clinical trials management.

Regulatory: RXDX is subject to oversight by multiple groups at the U.S. FDA including the Oncologic Drugs Advisory Committee for oncology drug development and Office of In Vitro Diagnostic Device Evaluation and Safety for companion diagnostics. There can be no assurance registration studies will be adequate to support regulatory filing with ODAC for RXDX-101 or any other pipeline product. Additionally, we expect the companion to diagnostic for RXDX-101 and other pipeline programs to be commercialized through diagnostic partners. There can be no assurance RXDX or its diagnostic partners will win timely PMA clearance for companion to RXDX-101 or any other pipeline product.

Competition: We are not aware of any other company developing a pan-inhibitor of ALK, ROS1 and TrkA/B/C. Additionally, there are currently no ROS1 or TrkA/B/C inhibitors approved for treatment of solid tumors in the U.S. or Europe. However, several companies have disclosed plans to develop therapies targeting TrkA/B/C. We believe RXDX-101 is currently the most advanced TrkA/B/C program in clinical development. There can be no assurance RXDX will be successful in maintaining its current leadership for timely commercialization of a TrkA/B/C inhibitor. Finally, several companies are developing second-generation ALK inhibitors with better blood-brain barrier than crizotinib. Some of these programs are more advanced than RGDX-101.

Financing: The company believes its financial resources will fund operations into at least 2017. However, depending on the pace of business development, RXDX may need additional capital to fund operations through Phase II proof-of-concept studies of RXDX-101. If Phase II studies are successful, RXDX may need access to additional capital through either internal sources or partnerships to fund registration studies and to fund commercialization. There can be no assurance RXDX will have access to capital in the future on adequate terms, or at all.

Partnership: RXDX will rely on partnerships with CROs, diagnostic product companies and other service providers to support clinical development and U.S. regulatory filings for RXDX-101 and its other pipeline programs. Additionally, we expect the company to seek commercial partners for RXDX-101 and its other pipeline programs in geographies outside the United States including Europe and Asia. There can be no assurance the partners will be successful in maintaining a steady supply of drug product, provide adequate support for clinical trials enrollment, optimize appropriate companion diagnostics or offer appropriate commercialization support in Europe, Asia and other regions outside the U.S. Lastly, the company licensed rights to RXDX-101 and RXDX-102 from Nerviano Medical Sciences. While Nerviano is not responsible for conducting any future clinical development, the two companies have signed a service agreement for additional manufacturing and clinical support services through 2014. There can be no assurance Nerviano will provide adequate support for timely future development of RXDX-101.

Product Liability: Pharmaceutical companies may face potential product liability lawsuits associated with adverse events – both currently identified and identified through future clinical trials and commercial experience. Product liability claims may result in limiting future product promotion, removal of one or more products from the market and potential for financial penalties and fines that may adversely impact RXDX's cash flow and financial position, including cash balance and ability to meet various debt covenants.

Limited Operating History: While the company was formed in 2012, RXDX had limited operations as a drug development company prior to May 2013. This limited operating history may restrict the scope of information available for investors to form an investment opinion. RXDX is classified as an emerging growth company and is entitled to more limited disclosure requirements, which may make shares of RXDX less attractive to investors. The company went public in November 2013 through a reverse merger and trading volume in shares of RXDX has limited due in part to the small number of registered shares. There can be no assurance that there will be a liquid and orderly market for trading of RXDX shares in the near term, or ever. Additionally, if one or more holders of common stock covered by an effective registration statement seeks to sell stock, the share price may be adversely impacted.

Debt Repayment: The company has a \$10M debt facility with Silicon Valley Bank Corp. that matures in December 2017. There can be no assurance RXDX will have adequate funds to repay the loan facility or that alternative debt financing will be available on acceptable terms, if at all.

APPENDIX A: IMPORTANT RESEARCH DISCLOSURES

ANALYST CERTIFICATION

I, Kevin DeGeeter, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm's total revenues, a portion of which is generated by investment banking activities.

Additional information regarding the contents of this publication will be furnished upon request. Please contact Ladenburg Thalmann, Compliance Department, 570 Lexington Avenue, 11th floor, New York, New York 10022 (or call 212-409-2000) for any information regarding current disclosures, and where applicable, relevant price charts, in regard to companies that are the subject of this research report.

COMPANY BACKGROUND

Ignyta is developing personalized oncology drugs using diagnostic tests to identify patients most likely to respond to therapy. The company's lead product RXDX-101, is a TrkA/B/C, ROS1, ALK inhibitor in Phase I development for the treatment of solid tumors. Ignyta hopes to move the program into Phase II development in 2015 for multiple indications including NSCLC. The San Diego-based company is also in pre-clinical development of other targeted cancer therapies based on proprietary Oncolome molecular expression database.

VALUATION METHODOLOGY

Our \$20.00 price target is based on a DCF analysis assuming 25% discount rate, 21.5 million shares on a fully diluted basis, terminal year (2022) FCF of \$168M and 15% long-term growth rate.

RISKS

These risk factors (clinical, regulatory, competition, financing, partnership, product liability, limited operating history, and debt repayment) do not constitute all the potential risks of investing in the subject company's shares. Investors should refer to the company's SEC filings including the most recent forms 10-K and 10-Q for further details on the risks associated with an investment in the subject company's shares.

STOCK RATING DEFINITIONS

Buy: The stock's return is expected to exceed 12.5% over the next twelve months.

Neutral: The stock's return is expected to be plus or minus 12.5% over the next twelve months.

Sell: The stock's return is expected to be negative 12.5% or more over the next twelve months.

Investment Ratings are determined by the ranges described above at the time of initiation of coverage, a change in risk, or a change in target price. At other times, the expected returns may fall outside of these ranges because of price movement and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review.

RATINGS DISPERSION AND BANKING RELATIONSHIPS AS OF (May 12, 2014)

Rating	%	IB %
BUY	74.5	55.0
NEUTRAL	25.5	43.1
SELL	0.0	0.0

COMPANIES UNDER ANALYST'S COVERAGE

ADMA Biologics, Inc. (ADMA)
 BG Medicine, Inc. (BGMD)
 diaDexus, Inc. (DDXS)
 Genetic Technologies, Ltd. (GENE)
 Mesoblast Ltd. (MBLTY)
 Navidea Biopharmaceuticals Inc. (NAVb)
 Opko Health, Inc. (OPK)
 Sequenom Inc. (SQNM)

Aeolus Pharmaceuticals Inc. (AOLS)
 CombiMatrix Corporation (CBMX)
 Exact Sciences Corp. (EXAS)
 Genomic Health Inc. (GHDX)
 Myriad Genetics Inc. (MYGN)
 Novavax, Inc. (NVAX)
 Ignyta, Inc. (RXDX)

COMPANY SPECIFIC DISCLOSURES

Ladenburg Thalmann & Co. Inc. makes a market in Ignyta, Inc..

Ladenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Ignyta, Inc. within the past 12 months.

Ladenburg Thalmann & Co. Inc. expects to receive compensation for investment banking and/or advisory services from Ignyta, Inc. within the next 3 months.


Ladenburg Thalmann & Co. Inc. intends to seek compensation for investment banking and/or advisory services from Ignyta, Inc. within the next 3 months.

Ladenburg Thalmann & Co. Inc received compensation for investment banking services from Ignyta, Inc. within the past 12 months.

Ladenburg Thalmann & Co. Inc had an investment banking relationship with the Ignyta, Inc. within the last 12 months.

INVESTMENT RATING AND PRICE TARGET HISTORY**Ignyta, Inc. Rating History as of 05/09/2014**

powered by: BlueMatrix



B=Buy N=Neutral S=Sell D=Drop Coverage I=Initiate NR=Not Rated

GENERAL DISCLAIMERS

Information and opinions presented in this report have been obtained or derived from sources believed by Ladenburg Thalmann & Co. Inc. to be reliable. The opinions, estimates and projections contained in this report are those of Ladenburg Thalmann as of the date of this report and are subject to change without notice.

Ladenburg Thalmann & Co. Inc. accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Ladenburg Thalmann & Co. Inc. This report is not to be relied upon in substitution for the exercise of independent judgment. Ladenburg Thalmann & Co. Inc. may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and Ladenburg Thalmann & Co. Inc. is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. Investors should consider this report as only a single factor in making their investment decisions.

Some companies that Ladenburg Thalmann & Co. Inc. follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Ladenburg Thalmann & Co. Inc. research reports may not be suitable for some investors. Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Securities recommended, offered or sold by Ladenburg Thalmann & Co. Inc. (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of some or all of principal invested. Indeed, in the case of some investments, the potential losses may exceed the amount of initial investment and, in such circumstances; you may be required to pay more money to support these losses.

The information and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy any securities mentioned herein. This publication is confidential for the information of

the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of Ladenburg Thalmann & Co. Inc.

Member: NYSE, NYSE MKT, FINRA, all other principal exchanges and SIPC

Additional Information Available Upon Request

©2014 - Ladenburg Thalmann & Co. Inc. All Rights Reserved.

EQUITY RESEARCH

ENERGY, POWER & INFRASTRUCTURE

Power & Electric Utilities

Brian J. Russo, CFA (646) 432-6312 brusso@ladenburg.com

Energy Exploration & Production, Master Limited Partnerships, Upstream

Noel A. Parks (212) 409-2023 nparks@ladenburg.com
Michael Schmitz, CFA (212) 409-2028 mschmitz@ladenburg.com

Master Limited Partnerships, Midstream

Eduardo Seda (212) 409-2034 eseda@ladenburg.com

Master Limited Partnerships, Downstream & Others

Richard A. Verdi (212) 409-2060 rverdi@ladenburg.com

Closed-End MLP Funds

Eduardo Seda (212) 409-2034 eseda@ladenburg.com

Water & Sustainable Infrastructure

Richard A. Verdi (212) 409-2060 rverdi@ladenburg.com

HEALTHCARE

Biotechnology

Matthew L. Kaplan (212) 891-5247 mkaplan@ladenburg.com

Biotechnology (BioPharmaceuticals)

Robert C. Hazlett, III (Bert) (212) 409-2062 rhazlett@ladenburg.com

Biotechnology (Personalized Medicine)

Kevin DeGeeter (212) 409-2027 kdegeeter@ladenburg.com

Healthcare Equipment & Medical Technologies

Jeffrey S. Cohen (305) 572-4110 jcohen@ladenburg.com

FINANCIAL INSTITUTIONS

Financial Services – Business Development Cos. & Specialty Finance

Mickey M. Schleien, CFA (305) 572-4131 mschleien@ladenburg.com

Financial Services – Equity REITs

Daniel P. Donlan (212) 409-2056 ddonlan@ladenburg.com
John J. Massocca (212) 409-2543 jmassocca@ladenburg.com

Financial Services – Mortgage REITs

David Walrod, CFA (212) 409-2031 dwalrod@ladenburg.com

TECHNOLOGY

Internet & Software Services

Jon R. Hickman (510) 918-4045 jhickman@ladenburg.com

TECHNICAL ANALYSIS

Adolfo R. Rueda, CMT (212) 409-2039 arueda@ladenburg.com

ADDITIONAL CONTACTS

Kenneth Brush, Head of Trading (212) 409-2011 kbrush@ladenburg.com
Eric Novotny (212) 409-2011 enovotny@ladenburg.com

570 Lexington Avenue 11th Floor New York, NY 10022 (212) 409-2000

NEW YORK, NY MELVILLE, NY BOSTON, MA MIAMI, FL NAPLES, FL BOCA RATON, FL HOUSTON, TX